DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Exforge HCT (Amlodipine Besylate / Hydrochlorothiazide / Valsartan) - Summary

 
 



WARNING: AVOID USE IN PREGNANCY

When pregnancy is detected, discontinue Exforge HCT as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury or death to the developing fetus [see Warnings and Precautions ].

 

EXFORGE HCT SUMMARY

Exforge HCT is a fixed combination of amlodipine, valsartan and hydrochlorothiazide.

Exforge HCT (amlodipine, valsartan, hydrochlorothiazide) is indicated for the treatment of hypertension.

This fixed combination drug is not indicated for the initial therapy of hypertension.
See all Exforge HCT indications & dosage >>

NEWS HIGHLIGHTS

Media Articles Related to Exforge HCT (Amlodipine / Hydrochlorothiazide / Valsartan)

Hypertension may be initiated by an autoimmune response
Source: Hypertension News From Medical News Today [2014.09.19]
High blood pressure is a major risk factor for heart attack, stroke, chronic heart failure, and kidney disease.

Dementia risk reduction through tobacco control and better prevention, detection and control of hypertension and diabetes
Source: Diabetes News From Medical News Today [2014.09.18]
The World Alzheimer Report 2014 'Dementia and Risk Reduction: An analysis of protective and modifiable factors', calls for dementia to be integrated into both global and national public health...

Men who improve their fitness levels can hold off development of hypertension
Source: Hypertension News From Medical News Today [2014.09.17]
A man's cardiorespiratory fitness can drastically delay the natural, age-associated increase of his blood pressure over his adult life span.

Experts raise concern over unnecessary treatment of mild hypertension in low risk people
Source: Hypertension News From Medical News Today [2014.09.15]
Lowering the drug threshold for high blood pressure (hypertension) has exposed millions of low-risk people around the world to drug treatment of uncertain benefit at huge cost to health systems...

Calorie restriction improves sleep apnea, hypertension in obese people
Source: Hypertension News From Medical News Today [2014.09.12]
Restricting calories may improve obstructive sleep apnea and reduce high blood pressure in obese adults, according to a study presented at the American Heart Association's High Blood Pressure...

more news >>

Published Studies Related to Exforge HCT (Amlodipine / Hydrochlorothiazide / Valsartan)

24-Hour ambulatory blood pressure response to combination valsartan/hydrochlorothiazide and amlodipine/hydrochlorothiazide in stage 2 hypertension by ethnicity: the EVALUATE study. [2010.11]
Several studies reported racial/ethnic differences in blood pressure (BP) response to antihypertensive monotherapy. In a 10-week study of stage 2 hypertension, 320/25 mg valsartan/hydrochlorothiazide (HCTZ) reduced ambulatory BP (ABP) significantly more effectively than 10/25 mg amlodipine/HCTZ...

Effects of force-titrated valsartan/hydrochlorothiazide versus amlodipine/hydrochlorothiazide on ambulatory blood pressure in patients with stage 2 hypertension: the EVALUATE study. [2009.06]
BACKGROUND: Previous studies using the combination of angiotensin-receptor blockers and hydrochlorothiazide (HCTZ) have shown superior ambulatory blood pressure (ABP) reduction in study participants with stage 2 hypertension compared with monotherapy. OBJECTIVE: This multicenter, double-blind, parallel group, forced-titration study of individuals with stage 2 hypertension, compared the efficacy of valsartan and amlodipine in combination with HCTZ on ABP reduction... CONCLUSION: On the basis of ABP monitoring but not office measurements, the fixed-dose combination of valsartan/HCTZ is a significantly more effective treatment regimen than amlodipine/HCTZ, with similar tolerability.

Clevidipine: a review of its use in the management of acute hypertension. [2009]
ABSTRACT: Clevidipine (Cleviprex), a late-generation dihydropyridine calcium channel antagonist available as a lipid emulsion for intravenous infusion, is approved in the US for the reduction of blood pressure (BP) when oral therapy is not feasible or desirable... Most adverse events associated with clevidipine were mild or moderate in severity and considered unrelated to study drug, with the most commonly reported being headache, nausea, chest discomfort, and vomiting.

Effects of valsartan or ramipril addition to amlodipine/hydrochlorothiazide combination on left ventricular mass in diabetic hypertensive patients with left ventricular hypertrophy. [2012]
CONCLUSIONS: Valsartan addition to dual therapy with amlodipine + HCTZ was more

24-Hour ambulatory blood pressure control with triple-therapy amlodipine, valsartan and hydrochlorothiazide in patients with moderate to severe hypertension. [2011.10]
To determine the effectiveness and safety of once-daily combination therapy with amlodipine, valsartan and hydrochlorothiazide for reducing ambulatory blood pressure (ABP) in patients with moderate to severe hypertension, a multicenter, double-blind study was performed (N=2271) that included ABP monitoring in a 283-patient subset.

more studies >>

Clinical Trials Related to Exforge HCT (Amlodipine / Hydrochlorothiazide / Valsartan)

Effectiveness of EXforge® and Nifedipine treAtment coMparison in Treating Chinese Hypertensive Patients [Recruiting]
This study is to demonstrate that valsartan/amlodipine 80/5 mg has superior efficacy compared with nifedipine 30mg alone in reducing the mean sitting diastolic blood pressure (MSDBP) and mean sitting systolic blood pressure (MSSBP) from baseline in patients with mild to moderate hypertension not adequately controlled with monotherapy.

EXforge As Compared to Losartan Treatment in Stage 2 Systolic Hypertension [Recruiting]
This study will compare the antihypertensive efficacy and safety of a valsartan/amlodipine-based treatment with a losartan-based treatment in patients with Stage 2 systolic hypertension (high blood pressure, mean systolic blood pressure greater than 160 and less than 200 mmHg.

Clinical Trial to Evaluate the Bioavailability and Safety of AGSAV301 [Recruiting]

Valsartan and Amlodipine Compared to Losartan and Amlodipine in Hypertensive Patients [Recruiting]
Hypertensive patients with moderate hypertension have a risk to develop cardiovascular events of 15-20% over a period of 10 years. It is important to reach quickly the advised target, but often this result can be obtained with a combination therapy. Some evidences demonstrate sartans and calcium channels blockers can be very useful and safe, but it is also important to verify which association can give side effects or give some pharmacokinetic interactions that can negatively influence the clinical combination efficacy.

Clinical Trial to Assess the Pharmacokinetic Characteristics of Lodivixx Tab. 5/160mg in Healthy Male Subjects [Recruiting]

more trials >>

Reports of Suspected Exforge HCT (Amlodipine / Hydrochlorothiazide / Valsartan) Side Effects

Hypertension (24)Oedema Peripheral (19)Blood Pressure Increased (18)Dizziness (15)Dyspnoea (15)Blood Pressure Decreased (15)Blood Pressure Fluctuation (13)Malaise (12)Back Pain (12)Pain (11)more >>


Page last updated: 2014-09-19

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014